# Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)

> **NCT00882947** · — · COMPLETED · sponsor: **Bayer** · enrollment: 38 (actual)

## Conditions studied

- Primary Hypertension

## Interventions

- **DRUG:** Ventavis (Iloprost, BAYQ6256)

## Key facts

- **NCT ID:** NCT00882947
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2009-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00882947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00882947, "Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00882947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*